Dr. Taplin on ARMOR 3-SV Trial for Patients with mCRPC

Mary-Ellen Taplin, MD
Published: Monday, Jul 11, 2016


Mary Ellen Taplin, MD, chair, executive committee for Clinical Research, director of Clinical Research, Lank Center for Genitourinary Oncology, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the ongoing ARMOR 3-SV trial for patients with metastatic castration-resistant prostate cancer (mCRPC).

Galeterone is an agent in development for this patient population, Taplin explains. It has a unique mechanism of action in that in addition to being an androgen receptor antagonist and a CYP17 lyase inhibitor, it also degrades the androgen receptor.

For this trial, patients will be screened for the presence of a blood-biomarker AR-V7. Patients who are AR-V7–positive and enrolled on the study will be randomized to receive galeterone or enzalutamide (Xtandi), with a primary endpoint of radiographic progression-free survival.

Mary Ellen Taplin, MD, chair, executive committee for Clinical Research, director of Clinical Research, Lank Center for Genitourinary Oncology, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the ongoing ARMOR 3-SV trial for patients with metastatic castration-resistant prostate cancer (mCRPC).

Galeterone is an agent in development for this patient population, Taplin explains. It has a unique mechanism of action in that in addition to being an androgen receptor antagonist and a CYP17 lyase inhibitor, it also degrades the androgen receptor.

For this trial, patients will be screened for the presence of a blood-biomarker AR-V7. Patients who are AR-V7–positive and enrolled on the study will be randomized to receive galeterone or enzalutamide (Xtandi), with a primary endpoint of radiographic progression-free survival.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x